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Abstract
Background: Cystic fibrosis (CF) is an inherited multi-system disorder characterised by chronic
airway infection with pathogens such as Pseudomonas aeruginosa.
Acquisition of P. aeruginosa by patients with CF is usually from the environment, but recent studies
have demonstrated patient to patient transmission of certain epidemic strains, possibly via an
airborne route. This study was designed to examine the survival of P. aeruginosa within artificially
generated aerosols.
Results: Survival was effected by the solution used for aerosol generation. Within the aerosols it
was adversely affected by an increase in air temperature. Both epidemic and non-epidemic strains
of P. aeruginosa were able to survive within the aerosols, but strains expressing a mucoid phenotype
had a survival advantage.
Conclusion: This would suggest that segregating individuals free of P. aeruginosa from those with
chronic P. aeruginosa infection who are more likely to be infected with mucoid strains may help
reduce the risk of cross-infection. Environmental factors also appear to influence bacterial survival.
Warming and drying the air within clinical areas and avoidance of humidification devices may also
be beneficial in reducing the risk of cross-infection.
Background
Cystic fibrosis (CF) is an inherited multi-system disorder
characterised by chronic airway infection, pancreatic
insufficiency, elevated sweat chloride concentration,
impaired fertility and hepatobiliary disease. The condi-
tion is due to mutations in the cystic fibrosis transmem-
brane conductance regulator (CFTR). Lack of CFTR
function results in reduced fluid secretion and excessive
fluid absorption, with a net effect of producing a thicken-
ing of the mucous component of the airway surface liq-
uid. This causes plugging of the sub-mucosal glands and
impairment of mucociliary clearance leading to infection,
inflammation, and tissue damage resulting in bron-
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gens such as Pseudomonas aeruginosa.
P. aeruginosa is the most common and clinically impor-
tant pathogen in patients with CF. The organism is a
Gram-negative, non-fermentative, aerobic bacillus
belonging to the family Pseudomonadaceae. Although
classified as an aerobic organism P. aeruginosa is a faculta-
tive anaerobe which may allow it to survive within the rel-
atively hypoxic lungs of patients with CF. It is ubiquitous
within the environment and is particularly isolated from
moist areas such as soil and water. The bacterium is fre-
quently found in environmental reservoirs, such as the
drains of hospital ward wash basins [1] and aerosols con-
taining P. aeruginosa can be detected when opening taps
[2,3]. The isolation of P. aeruginosa from tap water follows
contamination of the taps rather than the mains water
supply [4].
Acquisition of P. aeruginosa infection in patients with CF
can occur at any age. During early stages of P. aeruginosa
infection in patients with CF the bacteria are not usually
mucoid and can be cleared with aggressive antibiotic
treatment [5]. Once the patients lung becomes chronically
infected the bacteria change to a mucoid phenotype and
form biofilms. Most studies would suggest that 70–80%
of patients are infected during the teenage years [6]. A
number of studies have also demonstrated an association
between chronic P. aeruginosa infection and increased
mortality [7-9]. Acquisition of P. aeruginosa infection by
patients with CF is usually from the environment, but
recent studies have demonstrated patient to patient trans-
mission of certain strains of P. aeruginosa [10-13]. More
worryingly, some of these epidemic strains are associated
with increased morbidity and treatment burden when
compared to non-epidemic strains [14,15]. While the pre-
cise method of transmission of epidemic strains of P. aer-
uginosa remains unclear, there is evidence that airborne
transmission may be important [16,17] and therefore a
study was designed to investigate this further. The aims of
the study were to: 1) examine the effects of varying envi-
ronmental conditions on the survival of P. aeruginosa
within artificially generated aerosols; and 2) identify dif-
ferences in airborne survival of epidemic and non-epi-
demic strains under controlled environmental conditions.
Methods
Bacterial strains
P. aeruginosa (NCIMB 10848) was obtained from the
National Collection of Industrial and Marine Bacteria.
Isolates of both epidemic and non-epidemic strains of P.
aeruginosa were obtained from stored strains at the
Department of Microbiology, Leeds General Infirmary
and the Centre for Infectious Diseases, University of Edin-
burgh (See Table 1). The clinical strains of P. aeruginosa
used in this study were stored isolates originally collected
from patients with cystic fibrosis and genotyped as part of
routine clinical care and cross-infection surveillance. Dur-
ing this study no samples of sputum were obtained from
human subjects, therefore ethical approval was not
deemed to be necessary.
Preparation of frozen bacterial cultures
Bacteria of each strain examined were harvested from 200
ml of overnight, stationary liquid broth culture, washed,
and stored in 5 × 1 mL Eppendorf tubes with 40% (v v-1)
glycerol solution. The concentrated bacterial suspensions
were stored at -20°C until required.
Aerosol generation
All aerosol generation was undertaken in a negatively
pressurised Class II aerobiological chamber. Aerosols
were generated from 100 mL nebuliser solutions contain-
ing 105 CFU mL-1 of bacteria prepared from the frozen
bacterial cultures, using a Collison 3-jet nebuliser [18]
(BGI, USA) operating at 6 L min-1 and 103.4 kPa. The con-
centration of bacteria within the nebuliser suspension was
Table 1: Bacterial strains.
Bacterial strain Mucoid phenotype Epidemic strain Strain identification
Environmental No No NCIMB 10848
Unique CF No No 4412061*
Unique CF mucoid Yes No 43903641*
Manchester No Yes Jones et al [10]‡
Leeds Seacroft 1 No Yes 4390416-2*
Leeds Seacroft 2 No Yes 4390195*
Leeds Paediatric No Yes Denton et al [12]*
Leeds Paediatric mucoid Yes Yes Denton et al [12]*
Liverpool No Yes McCallum et al [11]‡
Liverpool mucoid Yes Yes McCallum et al [11]‡
*Stored strains obtained from the Department of Microbiology, Leeds General Infirmary originally isolated from people with cystic fibrosis 
identified through routine infection control surveillance to be epidemic or non-epidemic; ‡Strains obtained from Centre for Infectious Diseases, 
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dilution.
Laminar flow model
The aerosols were delivered into a 110 mm diameter air-
tight pipe with a variable length (See Figure 1). The rela-
tive humidity and temperature of the air within the appa-
ratus were controlled. In order to ensure a steady state
condition, samples were taken only after the apparatus
had run for 10 min. Thereafter, air samples were taken at
5 min intervals. Unless otherwise specified, relative
humidity and temperature were maintained at 45% ± 2%
and 22°C ± 2°C. All experiments were undertaken in trip-
licate. The velocity of the air within the laminar flow appa-
ratus was calculated to be 0.0491 m sec-1.
Air sampling
During each sampling event 56.6 L of air was drawn (i.e.
at a rate of 28.3 L min-1) through an Andersen 6-stage
impactor [19] (Andersen Inc, USA) containing nutrient
agar plates which were then incubated at 37°C for 24 hr.
The numbers of colonies on each plate were counted, and
the count corrected using published positive-hole correc-
tion tables [20]. The concentration of viable bacteria in
the air sample was then calculated. During experimenta-
tion the length of the laminar flow apparatus was varied
and air samples were taken in triplicate at lengths of 2, 3
and 4 m, which equates to mean aerosol ages of 40.3, 60.4
and 80.6 sec, respectively. In order to determine the size
distribution of the droplet nuclei generated, Stages 1–6 of
the Andersen sampler were used when the length of the
laminar flow apparatus length was 2 m. Thereafter, stages
5 and 6 only were used for apparatus lengths of 3 m and
4 m.
Experimental variables
In order to assess the impact of variations in the nebuliser
suspension fluid, aerosols were generated into the lami-
nar flow apparatus using variously 100 mL of distilled
water, 1/8 × Ringers, 1/4 × Ringers, 1/2 × Ringers, 1 ×
Ringers and 2 × Ringers solutions, and 10% (v v-1) foetal
bovine serum (FBS) containing 105 CFU mL-1 of P. aerugi-
nosa (NCIMB 10848) inoculated from the same frozen
sample.
In order to assess the impact of variations in temperature
on microbial survival, the temperature of the air within
the laminar flow model was maintained at either 22 ±
2°C or 27 ± 2°C, and 45% Relative Humidity (RH) by
adjustment of the air conditioning controls of the class II
aerobiological chamber. Aerosols were generated into the
laminar flow model using 100 mL of 1/4 × Ringers con-
taining 105 CFU mL-1 of P. aeruginosa (NCIMB 10848).
In order to assess the impact of variations in air humidity
on microbial survival, the relative humidity of the air
within the laminar flow model was maintained at either
45% RH or 67% RH, and 22 ± 2°C by adjustment of the
air conditioning controls of the class II aerobiological
chamber. Aerosols were generated into the laminar flow
model using 100 mL of 1/4 × Ringers containing 105 CFU
mL-1 of P. aeruginosa (NCIMB 10848).
Laminar flow modelFigure 1
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in the laminar flow model aerosols were generated into
the laminar flow model using 100 mL of 1/4 × Ringers
containing 105 CFU mL-1 of each strain of P. aeruginosa.
Statistical analysis
All data was expressed as a mean and standard error of
mean (SEM) The t-Test and one-way ANOVA was used for
analysis of different groups (GraphPad 5.01, GraphPad
Software Inc.). A p-value of < 0.05 was taken to be signif-
icant.
Results
Effect of nebuliser solution on survival of P. aeruginosa in 
aerosols
Aerosols containing P. aeruginosa (NCIMB 10848) when
generated using distilled water, 1/8 × Ringers, 1/4 × Ring-
ers, 1/2 × Ringers, 1 × Ringers and 2 × Ringers solutions,
and 10% FBS predominantly produce aerosols containing
particles of less than 2.0 μm in diameter (See Figure 2).
There was no significant difference between the percent-
age of particles with a diameter less than 2.0 μm between
the aerosols generated using the different nebuliser solu-
tions (One-way ANOVA p = 0.7404).
There was no significant difference between the concen-
tration of viable P. aeruginosa (NCIMB 10848) in the aer-
osols generated using 1/4 × Ringers and 1/2 × Ringers (p
= 0.0705), or 1 × Ringers (p = 0.5198), or 2 × Ringers (p =
0.055). Generation of aerosols using hypotonic solutions
resulted in a significant reduction in the concentration of
viable P. aeruginosa (NCIMB 10848) isolated from the aer-
osols compared to the use of isotonic Ringer's solution
(Distilled water v 1/4 × Ringers = 0.0276; 1/8 × Ringers v
1/4 × Ringers p = 0.0282). The concentration of viable P.
aeruginosa (NCIMB 10848) was significantly increased
when the aerosols generated using 10% FBS compared to
1/4 × Ringers (p = 0.0040) (See Figure 3).
Size distribution of particles sampled from aerosols containing P. aeruginosa (NCIMB 10848) generated using distilled water, dif-fer nt Ringer's s lutions and 10% FBSFigure 2
Size distribution of particles sampled from aerosols containing P. aeruginosa (NCIMB 10848) generated using 
distilled water, different Ringer's solutions and 10% FBS. Error bars represent standard error of mean.Page 4 of 10
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aeruginosa in aerosols
Conditions of high temperature or humidity did not affect
the size distribution of the aerosols. There was no change
in the size distribution of aerosol particles generated
under standard conditions (22°C, 45%RH), compared
with conditions of high temperature (27°C, 45% RH) and
high humidity (22°C. 67%RH). Under all three environ-
mental conditions the aerosols generated predominately
contained particles less than 2.0 μm diameter (See Figure
4). There was no significant difference between the three
environmental conditions in terms of percentage of parti-
cles less than 2.0 μm (One-way ANOVA p = 0.6508).
Generation of aerosols under conditions of increased tem-
perature resulted in a significant decrease in the concen-
tration of viable P. aeruginosa (p = 0.0114). The
concentration of viable P. aeruginosa was greater under
conditions of high humidity, but this did not reach statis-
tical significance (p = 0.1340) (See Figure 5).
Effect of different strains of P. aeruginosa in aerosols
All the strains of P. aeruginosa had similar aerosol particle
size distributions. All 10 strains tested produced aerosols
predominately containing particles less than 2.0 μm
diameter (See Figure 6). There was no significant differ-
ence between the 10 strains in terms of percentage of par-
ticles less than 2.0 μm (One-way ANOVA p = 0.4201).
The mucoid strains of P. aeruginosa produced aerosols
containing significantly higher concentrations of viable
bacteria than the non-mucoid strains (Liverpool p =
0.0181; Paediatric p = 0.0196; Unique CF p = 0.0264)
(See Figure 7).
Discussion
The laminar flow apparatus used in this study enabled
comparison of recovered concentrations of viable bacte-
ria, during steady state nebulisation, under controlled
environmental conditions. In addition to concentration
data, the study produced data regarding the size distribu-
tion of the aerosol particles containing viable bacteria in
the apparatus. Liquid particles suspended in an aerosol
are categorized as being either droplets or droplet nuclei.
Droplets are generally considered to be greater than 10
μm in diameter [21], whereas droplet nuclei are airborne
particles from which most of the liquid has evaporated
and therefore less than 10 μm in diameter [22,23]. Drop-
Concentration of viable P. aeruginosa (NCIMB 10848) at different aerosol ages generated using distilled water, different Ringer's solutio s nd 10% FBSFigure 3
Concentration of viable P. aeruginosa (NCIMB 10848) at different aerosol ages generated using distilled water, 
different Ringer's solutions and 10% FBS. Error bars represent standard error of mean.Page 5 of 10
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nuclei have a low terminal velocity and therefore can
potentially remain airborne for a number of hours. It has
been postulated that Gram negative bacteria such as P.
aeruginosa can only survive in droplets and not in droplet
nuclei, the implication being that respiratory droplet
nuclei are not implicated in the transmission of this path-
ogen [24]. The results of the laminar flow experiments
suggest that this is not the case, as they demonstrate that
P. aeruginosa can survive within droplet nuclei in artifi-
cially generated aerosols, with mucoid strains in particular
surviving well in an aerosolised state. In so doing, we have
demonstrated that aerial dissemination may be a plausi-
ble route of transmission for P. aeruginosa infection.
The Andersen 6-stage sampler is a standard piece of equip-
ment and is probably the most widely used aerobiological
sampler [25]. While our experiments demonstrated that it
is possible to recover P. aeruginosa from bioaerosols using
an Andersen 6-stage impactor, it is important to remem-
ber that the concentration cultured using the sampler may
not be a true representation of the actual concentration of
bacteria within the air. It has been estimated that the
quantity of bacteria cultured from an air sample repre-
sents only approximately 10% of the actual bacterial bur-
den, with the remaining 90% in a viable but non-
culturable state [26]. Gram-negative bacteria are particu-
larly vulnerable to the shear forces imposed during the
sampling process. Consequently, it is generally thought
that air samples in the clinical setting tend to underesti-
mate the numbers of Gram-negative bacteria present in
the air. Notwithstanding this, it is not known the extent to
which these viable but non-culturable bacteria represent a
potential risk for infection.
Our experiments demonstrated that the solution used for
nebulisation is critical for the survival of the bacteria
within aerosols. The use of hypotonic solutions produced
a significant reduction in the ability of the bacteria to sur-
vive within the aerosol. Inoculation of bacteria into a
hypotonic solution will result in an osmotic shock. How-
ever, in our experiments we found that this was not suffi-
cient to kill the bacteria, as the control counts from the
nebuliser remained stable pre- and post-nebulisation; it
Size distribution of particles sampled from aerosols containing P. aeruginosa (NCIMB 10848) generated using Ringer's solutions into conditions of normal temperature and humidity (22°C 45% RH), high temperature (27°C 45% RH) or high humidity (22°C67%RH)Figure 4
Size distribution of particles sampled from aerosols containing P. aeruginosa (NCIMB 10848) generated using 
Ringer's solutions into conditions of normal temperature and humidity (22°C 45% RH), high temperature 
(27°C 45% RH) or high humidity (22°C 67%RH). Error bars represent standard error of mean.Page 6 of 10
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the bacteria in a weakened state so that subsequent sur-
vival in an aerosol is significantly reduced. The reduction
in survival may also have been due to the increase in the
boiling temperature that occurs with the addition of a sol-
ute to a solution. An increase in the boiling temperature
will result in a reduced rate of evaporation and hence pro-
tect the bacteria from the lethal effects of desiccation. The
solution which allowed for the greatest survival of bacteria
was 10% FBS. This solution will not only protect the bac-
teria from osmotic shock and desiccation, but also con-
tains nutrients that will allow the bacteria to continue
metabolising whilst suspended in the aerosol. In many
respects this represents the case for bioaerosols produced
by patients with CF, who will tend to liberate microorgan-
isms in aerosols containing salts and proteinaceous mate-
rial.
The environmental conditions of the aerosol are impor-
tant for survival of bacteria within droplet nuclei. Bacteria
are more rapidly desiccated in conditions of high temper-
ature or low relative humidity. The data presented here
confirms that the survival of P. aeruginosa is adversely
effected by a small increase in temperature. However,
increased humidity did not statistically improve the sur-
vival of P. aeruginosa within the aerosol. Both of these
effects may have potential clinical implications as it
would suggest patients with CF should avoid cool and
damp air conditions in an effort to minimise infection
with P. aeruginosa. Consideration should be made to the
environmental air conditions when CF units are been
designed. Potentially the use of warm and dry air may
reduce the risk of cross-infection by P. aeruginosa between
patients with CF. It would also seem reasonable to advise
patients with CF to avoid the use of devices such as
humidifiers as they may promote the survival of P. aerugi-
nosa within aerosols.
The presence of a mucoid phenotype seems to be particu-
larly important for the survival of P. aeruginosa with an
aerosol. Isolates of the Liverpool, Leeds Paediatric and
Unique CF strains expressing both a mucoid and non-
mucoid phenotype were studied in the laminar flow appa-
ratus. For all the strains the presence of a mucoid pheno-
type resulted in significantly increased concentrations in
the aerosols. The mucoid strains over-produce the exopol-
ysaccaride alginate which has been implicated in the per-
sistence and pathogenesis of chronic P. aeruginosa
Concentration of viable P. aeruginosa (NCIMB 10848) at different aerosol ages generated using Ringer's solutions into condi-ti s normal temperature nd humidity (22°C 45% RH), high temp ature (27°C 45% RH) or high humidity (22°C 67%RH)Figure 5
Concentration of viable P. aeruginosa (NCIMB 10848) at different aerosol ages generated using Ringer's solu-
tions into conditions normal temperature and humidity (22°C 45% RH), high temperature (27°C 45% RH) or 
high humidity (22°C 67%RH). Error bars represent standard error of mean.Page 7 of 10
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improve the survival of the P. aeruginosa in aerosols by
providing a protective barrier which reduces the lethal
effects of desiccation upon the bacteria.
The data presented from this study provides support for
the hypothesis that airborne dissemination may be
important for the cross-infection of P. aeruginosa between
patients with CF. There have been two studies that have
demonstrated that patients with CF can produce aerosols
containing viable P. aeruginosa [16,17] as well as a study
demonstrating that Burkholderia cepacia complex can be
disseminated from patients with CF during physiotherapy
[28]. A further study only published in abstract form
examining the frequency of bacterial shedding in the out-
patients setting demonstrated that respiratory pathogens
were more frequently cultured from the hands and air-
borne droplets of patients with CF than from environ-
mental surfaces or equipment [29]. The sampling at the
Liverpool CF unit demonstrated that the outbreak strain
P. aeruginosa could be cultured from the air 3 hours after
a patient had left the area. To survive this length of time
suspended within an aerosol the bacteria must be in a
droplet nuclei, because larger droplets would have fallen
to the floor due the effect of gravity.
Although this study is limited in that the aerosol residency
time for the laminar flow apparatus was relatively short at
only just over 1 minute, this was however long enough for
the bacteria to travel 4 m – conclusively demonstrating
that the bacteria were transported in droplet nuclei and
not in droplet form. The concentrations of P. aeruginosa
used in the present study were lower than those com-
monly found in sputum samples from patients with CF
which can contain approximately 107 CFU g-1 [30].
Although it is theoretically possible that the inhalation of
just a few bacteria might result in colonisation, the dose of
P. aeruginosa required to cause pulmonary infection in
patients with CF is not known
Conclusion
There appears to be little difference in airborne survival
between the epidemic and non-epidemic strains of P. aer-
uginosa expressing a non-mucoid phenotype. However the
expression of the mucoid phenotype does seem important
for survival within droplet nuclei. This suggests that par-
Size distribution of particles sampled from aerosols containing different strains of P. aeruginosa generated using Ringer's solu-tionsFigure 6
Size distribution of particles sampled from aerosols containing different strains of P. aeruginosa generated 
using Ringer's solutions. Error bars represent standard error of mean.Page 8 of 10
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als free from P. aeruginosa from those with chronic
infection who are more likely to be infected with mucoid
strains of P. aeruginosa.
Finally, our study suggests that environment appears to
influence bacterial survival and optimal conditions for
reducing airborne transmission of P. aeruginosa between
patients could include warming and drying the air within
clinical areas and avoidance of humidification devices.
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